PERSONAL DATA:

Name: Ombretta Melaiu
DOB: Massa Marittima (GR), 13th April 1985
Citizenship: Italian
Institution: Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata",
e-mail address: Ombretta.Melaiu@uniroma2.it; ombretta.melaiu@opbg.net

RESEARCH INTEREST:

Translational studies on immune-oncology field.
Tumor immune microenvironment: studies aimed at elucidating the role of tumor-infiltrating immune cells in affecting clinical outcomes of paediatric and adult cancers.
Immunotherapy: studies focused on developing new oncological treatment that bolster the immune response in the fight against tumor cells.
Cancer predisposition: studies on the genetic susceptibility in the development of cancer and aimed to identify genes playing a key role in the carcinogenesis to be exploited as therapeutic targets.

LS SECTION:

LS6 (LS6_1 Innate Immunity; LS6_2 Adaptive Immunity; LS6_3 Regulation of Immune Response; LS6_11 Innovative immunological tools and approaches, including therapies)
LS2 (LS2_1: Genetics)
LS3 (LS3_12: Organoids)
LS4 (LS4_12: Cancer)

EDUCATION:

2007: BSc (110/110 cum laude) in Biological and Molecular Science at University of Pisa, Pisa, Italy.
2009: MSc (110/110 cum laude) in General Pathophysiological Sciences - Biology 6/S class at University of Pisa, Pisa, Italy.
2013: PhD in Biological and Molecular Sciences at University of Pisa, Pisa, Italy.
2017: Specialization (50/50 cum laude) in Pathology and Clinical Biochemistry at University of Rome "Tor Vergata", Rome, Italy.

CURRENT POSITIONS:

Assistant Professor (Type B fixed-term researchers, RTDB) at University of Rome "Tor Vergata", Department of Clinical Sciences and Translational Medicine, Rome, Italy since 1st February 2022.

Researcher at Bambino Gesù Children's Hospital, Oncohematology Department, Rome, Italy.

PREVIOUS POSITIONS:

June 2020–January 2022: Researcher at Bambino Gesù Children's Hospital, Oncohematology Department, Rome, Italy. Research activity: Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy.

June 2017–May 2020: Type A fixed-term researchers (RTDA) at University of Pisa, Pisa Italy. Research activity: Characterization of genes involved in the malignant pleural mesothelioma; study of genetic predisposition of multiple myeloma.

June 2017–May 2020: Affiliated researcher at Bambino Gesù Children's Hospital, Oncohematology Department, Rome, Italy. Research activity: Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy.

May 2015–May 2017: Research Fellowship at Bambino Gesù Children's Hospital, Oncohematology Department, Rome, Italy. Research activity: Characterization of tumor-infiltrating T lymphocytes in therapy-resistant neuroblastoma patients. The research was supported by the individual Research Fellowship Fondazione Umberto Veronesi (2017).

April 2013–April 2015: Research Fellowship at University of Pisa, Department of Biology, Genetics, Pisa, Italy; Research activity: Study of new biomarkers for the clinical surveillance of workers previously exposed to asbestos.

April 2012–December 2012: Visiting scientist at Imperial College, Oncology and Surgery Department, London, UK; Research activity: Identification and characterization of genes involved in the malignant pleural mesothelioma.

QUALIFICATION FOR SECOND CLASS PROFESSOR:

From 31/01/2022 to 31/01/2031 SSD 06/N1 - SCIENZE DELLE PROFESSIONI SANITARIE E DELLE TECNOLOGIE MEDICHE APPLICATE (ASN session 2021/2023)
From 31/01/2022 to 31/01/2031 SSD 06/A2 PATOLOGIA GENERALE E PATOLOGIA CLINICA (ASN session 2021/2023)
From 31/01/2022 to 31/01/2031 SSD 05/I1 - GENETICA (ASN session 2021/2023)

PROFESSIONAL SKILLS:

Cellular Biology: Human cell isolation from peripheral blood. Cell cultures. Cell transfections and infections with lentiviral vectors. Apoptosis, Cytotoxic, Proliferation assays. Microfluidic device management. Flow Cytometry. Human and murine tumor spheroids and cancer organoids generation.
Molecular Biology: Purification and extraction of RNA, DNA, proteins. Real Time-qPCR for gene/miRNA expression and genotyping. Automatic Sequencing. Western Blotting. ELISA. Molecular cloning techniques. Site-directed mutagenesis. Luciferasy assay. Chromatin immunoprecipitation. Nanostring assay. Exome sequencing. Proteome Profiler Mouse/Human Chemokine Array.
In vivo skills: Mouse model knowledge and management.
Digital Pathology: Immunohistochemistry. Multiplex Immunofluorescence. RNAscope. Imaging Mass Cytometry.
Sequencing data analysis: Venn Diagramm; Gene onthology analysis of RNA-Seq experiments. UCSC Genome-Browser. Blast and Primers design tools. Gene Prospector, Coremine, SNPs3D; Webgestalt Gene, Onto-Express, DAVID Functional Annotation Bioinformatics tool; Miranda, Mirbase and Target-scan. Tgex, IGV for BAM and VCF files.

INFORMATIC SKILLS:

OS: Windows XP, Vista, 7 and 10; MacOS
Languages: HTML
Application Software: Office; Photo Editor Photoshop CS6; Adobe Illustrator; e-mail application; BD FACS Diva
Other: Pubmed and Medline

AWARDS:

2021: Competition winner as Assistant Professor (RTDB) at Sapienza University of Rome, Rome, Italy, SSD 06/N1.
2021: Fondazione Umberto Veronesi Award.
2018: TRAVEL GRANT to European Congress of Immunology 2018 (Amsterdam).
2014: Award for Best poster presentation at the XIII Congress of the Italian Federation of Life Sciences (Pisa Italy. Title: Are MSLN, CFB and CCNO cancer genes of mesothelioma?).

CONFERENCE PARTICIPATION AS ORAL PRESENTER:

2021: 17th international conference on computational intelligence methods for bioinformatics and biostatistics CIBB. Title: Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma.
2021: Advances in Neuroblastoma Research (ANR). Title: Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma.
2017: Giornata Romana di Immunologia. Rome. Title: Dissecting the tumor immune microenvironment in neuroblastoma.
2015: IV Workshop AIEOP in lab. Napoli. Title: Ruolo dei linfociti T infiltranti il tumore come potenziali marcatori prognostici e terapeutici in pazienti affetti da forme aggressive di neuroblastoma.

2013: Osservatorio Nazionale Amianto (ONA) Convegno giuridico-scientifico. Pisa. Title: Le ultime acquisizioni scientifiche in materia di mesotelioma.
2013: Società Italiana di Mutagenesi Ambientale. Padova. Title: Comparative Genomic Hybridization Studies on Mesothelioma show a Parallel Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group.
2011: Società Italiana di Mutagenesi Ambientale. Parma. Title: Identification and characterization of genes involved in the malignant pleural mesothelioma.

POSITION HELD IN SCIENTIFIC ACTIVITY:

- Member of SIICA (Società Italiana di Immunologia e Allergologia) since 2018
- Reviewer since 2020 of International Peer Review Journals: Cancers, Diagnostics, Mutagenesis, International Journal of Molecular Science.

FUNDING FOR RESEARCH SUPPORT:

Position Held as **Principal Investigator:**

2020: Finanziamento di Ateneo "Rating60%2020" from University of Pisa, Pisa, Italy (12 months).
2019: Bando Ricerca Finalizzata 2019. Project title: Autophagy manipulation as a novel strategy for stimulating the immune response in neuroblastoma. Coordinator of Operative Unit, GR-2019-12369231 (36 months).
2018: Finanziamento di Ateneo "Rating60%2018" from University of Pisa, Pisa, Italy (12 months).
2017: Fondazione Umberto Veronesi Fellow. Project title: Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy (12 months).
2017: Finanziamento delle Attività di Base di Ricerca (FFABR) from Agenzia nazionale di valutazione del sistema universitario e della ricerca (ANVUR) (12 months).

Position Held as **Co-Investigator**:

2020: Associazione Italiana per la Ricerca sul Cancro (AIRC)-Investigator Grant (IG24345). Project title: Functional immune characterization of the neuroblastoma microenvironment to develop personalized cancer immunotherapy (36 months).
2018: Associazione Italiana per la Ricerca sul Cancro (AIRC)-Investigator Grant (IG2018). Project title: Identification and characterization of deregulate genes in malignant pleural mesothelioma (36 months).
2018: PRA 2018–2019 grant, project code -PRA_2018_39, University of Pisa. Project title: Interazione tra recettori del gusto e microbioma (24 months).
2016: Associazione Italiana per la Ricerca sul Cancro (AIRC)-Investigator Grant (IG18495). Project title: Dissecting the immune heterogeneity of neuroblastoma microenviroment to improve patient risk stratification and therapy (36 months).
2015-2020: Ricerca Corrente, Ministero della Salute.
2013: Bando ricerca finalizzata RF-2009-1529895 (36 months).

TEACHING EXPERIENCE AND SUPERVISION OF GRADUATE STUDENTS:

- 2022-present: Professor of Clinical Pathology for the MSc Degree Course in Dentistry and Dental Prosthetics at University of Rome "Tor Vergata".
- 2022-present: Professor of Clinical Pathology for the BSc Degree Course in Sciences and Diagnostic technologies at University of Rome "Tor Vergata".
- 2017-2020: Professor of "Genetics" for the BSc Degree Course in Biological Sciences at University of Pisa.
- 2017-2020: Professor of Genetics and Genomics analyses for the MSc Degree Course in Cellular and Molecular Biology at University of Pisa.
- 2018/2019: Correlator of 2 MSc degree thesis (students: Marco Calvigioni and Gabriele Parlanti) at University of Pisa.
- Co-tutorship of 1 BSc student: Giulio Ciucci, 2011/2012-Biological Science; and 5 MSc students: Chiara De Santi, Elisa Bracci, Mariasole Facioni (2011/2012); Calogerina Catalano, Giovanni Giangreco (2013/2014) for Degree Course in Cellular and Molecular Biology at University of Pisa.

LIST OF PUBLICATIONS

1. D'Amico S, D'Alicandro V, Compagnone M, Tempora P, Guida G, Romania P, Lucarini V, **Melaiu O**, Falco M, Algeri M, Pende D, Cifaldi L, Fruci D.
   ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. Front Immunol. 2021 Nov 30;12:778103.

2. Bussola N*, Papa B*, **Melaiu O**, Castellano A, Fruci D, Jurman G.
   Quantification of the Immune Content in Neuroblastoma: Deep Learning and Topological Data Analysis in Digital Pathology. Int J Mol Sci. 2021 Aug 16;22(16):8804. *first authors.

3. Morani F, Bisceglia L, Rosini G, Mutti L, **Melaiu O**, Landi S, Gemignani F.
   Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. Int J Mol Sci. 2021 Mar 8;22(5):2738.

4. D'Amico S, Tempora P, Lucarini V, **Melaiu O**, Gaspari S, Algeri M, Fruci D.
   ERAP1 and ERAP2 enzymes: a protective shield for RAS against COVID-19? Int J Mol Sci. 2021 Feb 8;22(4):1705.

5. Lucarini V†, **Melaiu O†**, Tempora P, D'Amico S, Locatelli F, Fruci D.
   Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. Cancers (Basel). 2021 Jan 23;13(3):433. **† = first author equally contributed.**

6. Veneziani I, Infante P, Ferretti E, **Melaiu O**, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, Cifaldi L.
   Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. Cancer Immunol Res. 2021 Feb;9(2):170-183..

7. Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, **Melaiu O**, Giordano A, Luzzi L, Gemignani F, Landi S.
   Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. Invest New Drugs. 2020 Dec 9. doi: 10.1007/s10637-020-01040-y.

8. **Melaiu O**, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, Cifaldi L, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D.
   Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nat Commun. 2020 Nov 25;11(1):5992.

9. **Melaiu O**, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, Grząśko N, Moreno V, Jurczyszyn A, Jerez A, Watek M, Varkonyi J, Garcia-Sanz R, Kruszewski M, Dudziński M, Kadar K, Jacobsen SEH, Mazur G, Andersen V, Rybicka M, Zawirska D, Raźny M, Zaucha JM, Ostrovsky O, Iskierka-Jazdzewska E, Reis RM, Stępień A, Beider K, Nagler A, Druzd-Sitek A, Marques H, Martìnez-Lopez J, Lesueur F, Avet-Loiseau H, Vangsted AJ, Krawczyk-Kulis M, Butrym A, Jamroziak K, Dumontet C, Vogel U, Rymko M, Pelosini M, Subocz E, Szombath G, Sarasquete ME, Silvestri R, Morani F, Landi S, Campa D, Canzian F, Gemignani F.
   Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33377.

10. **Melaiu O**, D'Amico S, Tempora P, Lucarini V, Fruci D.
Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection. Int J Mol Sci. 2020 Aug 15;21(16):5861. doi: 10.3390/ijms21165861.

11. Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, **Melaiu O**, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, Landi S.
EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma. Int J Mol Sci. 2020 Jul 9;21(14):4856. doi: 10.3390/ijms21144856.

12. **Melaiu O**, Lucarini V, Giovannoni R, Fruci D, Gemignani F.
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol. 2020 Jul 10:S1044-579X(20)30156-5. doi: 10.1016/j.semcancer.2020.07.001.

13. Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C, Pacella I, Accapezzato D, Lancellotti F, Sacco L, Caronna R, **Melaiu O**, Fruci D, D'Oria V, Manzi E, Sagnotta A, Parrino C, Coletta D, Peruzzi G, Terenzi V, Battisti A, Cassoni A, Fadda MT, Brozzetti S, Fazzi K, Grazi GL, Valentini V, Chirletti P, Polimeni A, Barnaba V, Timperi E.
Genetically driven CD39 expression shapes human tumor-infiltrating CD8+ T-cell functions. Int J Cancer. 2020 Nov 1;147(9):2597-2610.

14. Gemignani F, Romei C, Ciampi R, Corrado A, **Melaiu O**, Figlioli G, Bonotti A, Foddis R, Cristaudo A, Pellegrini G, Vivaldi A, Cipollini M, Landi S, Elisei R. Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma. Thyroid. 2020 Mar 31. doi: 10.1089/thy.2019.0352

15. **Melaiu O**, Lucarini V, Cifaldi L, Fruci D.
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. Front Immunol. 2020 Jan 21;10:3038.

16. Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Severini L, Talbot J, **Melaiu O**, Tanori M, Di Magno L, Bellavia D, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Doriana Fruci D,* Di Marcotullio L.
ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP. Nat Commun. 2019 Jul 24;10(1):3304. doi: 10.1038/s41467-019-11093-0.

17. Cipollini M, Luisi S, Piomboni P, Luddi A, Landi D, **Melaiu O**, Figlioli G, Garritano S, Cappelli V, Viganò P, Gemignani F, Petraglia F, Landi S.
Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis. Fertil Steril. 2019 Aug;112(2):343-352.e1.

18. Cammarata I, Martirea C, Citroa A, Raimondo D, Fruci D, **Melaiu O**, D'Oria V, Carone C, Peruzzi G, Cerboni C, Santoni A, JSidney J, Sette A, Paroli M, Caccavale R, Milanetti E, Riminucci M, Timperi E, Piconese S, Manzo A, Montecucco C, Scrivo R, Valesini G, Cariani E, Barnaba V. Journal of autoimmunity.
Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis. J Autoimmun. 2019 May;99:81-97.

19. Boldrini R*, De Pasquale MD*, **Melaiu O***, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, Fruci D. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant

extracranial germ-cell tumors. Oncoimmunology. 2018 Dec 13;8(2):e1542245. ***Equally contribution.**

20. D'Alicandro V, Romania P, **Melaiu O**, Fruci D. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. Mol Immunol. 2018 Apr 3. pii: S0161-5890(18)30103-2.

21. **Melaiu O**, Gemignani F, Landi S.
The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis. 2018 Jan;10(Suppl 2):S246-S252.

22. Romania P, Cifaldi L, Pignoloni B, Starc N, D'Alicandro V, **Melaiu O**, Li Pira G, Giorda E, Carrozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, Fruci D.
Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion. Cell Rep. 2017 Jul 25;20(4):846-853.

23. Brandetti E, Veneziani I, **Melaiu O**, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L.
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology. 2017 Apr 20;6(6):e1316439.

24. De Santi C*, **Melaiu O***, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017 Jun 9;7(1):3140. ***Equally contribution.**

25. **Melaiu O**, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes Cancer. 2017 Jan;8(1-2):438-452.

26. Bonotti A, Foddis R, Landi S, **Melaiu O**, De Santi C, Giusti L, Donadio E, Ciregia F, Mazzoni MR, Lucacchini A, Bovenzi M, Comar M, Pantani E, Pistelli A, Cristaudo A.
A Novel Panel of Serum Biomarkers for MPM Diagnosis. Dis Markers. 2017;2017:3510984.

27. De Santi C, Pucci P, Bonotti A, **Melaiu O**, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occup Environ Med. 2017 Jun;74(6):456-463.

28. **Melaiu O**, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D.
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clin Cancer Res. 2017 Aug 1;23(15):4462-4472.

29. Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, **Melaiu O**, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddis R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, Landi S. Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. DNA Repair (Amst). 2016 May;41:27-31.

30. Figlioli G, Elisei R, Romei C, **Melaiu O**, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S.
A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):700-13.

31. Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, **Melaiu O**, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S.
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. Arch Toxicol. 2016 Dec;90(12):3099-3109.

32. **Melaiu O**, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.
Expression status of candidate genes in mesothelioma tissues and cell lines. Mutat Res. 2015 Jan;771:6-12.

33. Garritano S, De Santi C, Silvestri R, **Melaiu O**, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. J Thorac Oncol. 2014 Nov;9(11):1662-8.

34. **Melaiu O**, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014. Erratum in: PLoS One. 2017 Jun 22;12 (6):e0180317.

35. Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L, Frixa T, Landi D, Cancemi L, De Santi C, **Melaiu O**, Foddis R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, Landi S. Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2121-5.

36. **Melaiu O**, Facioni MS, Cabiati M, Caruso R, Giannessi D, Landi S, Gemignani F, Del Ry S.
Characterization of novel 3'untranslated regions and related polymorphisms of the gene NPPC, encoding for the C-type natriuretic peptide. Peptides. 2013 Jun;44:93-9. doi: 10.1016/j.peptides.2013.03.012. Epub 2013 Mar 28.

37. Stebbing J, Lit LC, Zhang H, Darrington RS, **Melaiu O**, Rudraraju B, Giamas G.
The regulatory roles of phosphatases in cancer. Oncogene. 2014 Feb 20;33(8):939-53. doi: 10.1038/onc.2013.80. Epub 2013 Mar 18.

38. **Melaiu O**, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F, Pellegrini S, Landi S.
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res. 2012 Apr-Jun;750(2):132-40.

39. Caselli C, **Melaiu O**, Maltinti M, Del Ry S, Cabiati M, Prescimone T, Neglia D, Giannessi D.
A methodological reappraisal of total and high molecular weight adiponectin determination in human peripheral circulation: comparison of four immunometric assays. Clin Chem Lab Med. 2010 Apr;48(4):561-8.